Temozolomide

CNS Drugs

Volumn 12, Issue 3, 1999, Pages 237-243

  Hvizdos, Karen M ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PROCARBAZINE; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAIN CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HUMAN; LETHARGY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0032831777     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199912030-00006     Document Type: Review

References (28)

1. Kaha SE, Kvritvis AP. Recognition and management of gliomas. Drugs 1997 Feb; 53: 235-44
2. Levin VA Leibel SA, Gutin PH. Neoplasms of the central nervous system. In: DeVita VT, Hellman S. Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia (PA): Lippincott-Raven. 1997: 2013-82
3. Henny BJ, Wheelhouse RT, Stevens MFG. et al. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994 Aug 9; 33: 9045-51
4. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations overide alkviwansferase in conferring resistance to temozolomide but not to 1.3-bis (2-chloroethylinitrosourca. Cancer Res 1996 Dec 1; 56: 5375-9
5. Friedman HS, Johnson SP, Dong Q, et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multifornic xenograft. Cancer Res 1997 Jul 15; 57: 2933-6
6. Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbarnoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831). a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987 Nov 15; 47: 5846-52
7. Friedman HS, Dolan ME, Pegg AE, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995 Jul 1; 55: 2853-7
8. Newlands ES, Blackledge GRP, Slack JA, et al. Phase I trial of remozolomide (CCRG 81045: M & B 39831: NSC 362856). Br J Cancer 1992 Feb; 65: 287-91
9. Dhodapkar M, Rubin J, Reid JM, et al. Phase I trial of temozoiomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 1997 Jul; 3: 1093-100
10. Reidenberg P, Statkevich P, Judson I, et al. Effect of food on the oral bioavailability of temozolomide, a new chemotherapeutic agent [abstract P111-44]. Clin Pharmacol Ther 1996 Feb; 59: 199
11. SP Europe. Temozolonide prescribing information. Brussels, Belgium, 1999
12. Block CS, Matthews JC, Brown G. et al. Demonstration and auantitation of temozolomide uptake in vivo in human brain tumours [abstract 488]. Ann Oncol 1996; 7 Suppl. 1: 137.
13. Brock CS, Mathews JC, Brown G, et al. Response to temozolomide in recurrent high grade gliomas is related to tumour drug concentration (abstract 667). Ann Oncol 1998; 9 Suppl. 2; 174
14. Reid JM, Stevens DC, Rubin J. et al. Pharmacokinetics of methyl (triazen-l-yl) imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 1997 Dec; 3 (Pt I); 2393-8
15. Estlin EJ, Lashford L, Ablett S, et al. Phase I study of temozolomide in paediatric patients with advanced cancer. Br J Cancer 1998 Sep; 78: 652-61
16. O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer A 1993; 29A (7): 940-2
17. Bower M, Newlands ES, Blcehen NM, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997 Oct; 40: 484-8
18. Newlands ES, O'Reilly SM, Glaser MG, et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer A 1996 Dec; 32A: 2236-41
19. Prados M, Yung A, Chang S, et al. A phase II trial of Temodal® (temozolomide) in patients with anaplastic astrocytoma at first relapse [abstract 533]. 35th Proc Am Soc Clin Oncol 1999 May; 18: 139a
20. Schering Temodal® tumor response supports astrocytoma, not glioblastoma. FDC Pink 1999 Jan 18; 61: 3-4
21. Osoba D, Levin V, Yung WKA, et al. Health-related quality of life benefits in patients with recurrent anaplastic astrocytoma treated with temozolomide [abstract 1496]. 34th Proc Am Soc Clin Oncol 1998 May; 17: 388a
22. Yung A, Levin VA, Albright R, et al. Randomized trial of Temodal vs. procarbazine in glioblastoma multiforme at first relapse [abstract 532]. 35th Proc Am Soc Clin Oncol 1999 May; 18: 139a
23. Osoba D, Brada M, Yung WKA. Health-related quality of life benefits of treatment with temozolomide versus procarbazine in patients with glioblastoma multiforme [abstract 541]. 35th Proc Am Soc Clin Oncol 1999 May; 18: 141a
24. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltansferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998 Dec; 16: 3851-7
25. Newlands ES, Stevens MFG, Wedge SR, et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997 Jan; 23: 35-61
26. Nicholson HS, Krailo M, Ames MM, et al. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group. J Clin Oncol 1998 Sep; 16: 3037-43
27. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998 Oct 1; 58: 4363-7
28. Levin V, Yung A, Prados M, et al. Phase II study of Temodal® (temozolomide) at first relapse in anaplastic astrocytoma patients [abstract 1370]. 33rd Proc Am Soc Clin Oncol 1997 May; 16: 384a